"Designing Growth Strategies is in our DNA"

Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027

Last Updated: May 26, 2025 | Format: PDF | Report ID: FBI104668

 


To get information on various segments, share your queries with us

  ATTRIBUTE

  DETAILS

Study Period

  2016-2027

Base Year

  2019

Forecast Period

  2020-2027

Historical Period

  2016-2018

Unit

  Value (USD million)

Segmentation

By Drug Class

  • Prophylaxis
    • Palivizumab
    • Nirsevimab
    • MK-1654
    • Other Prophylaxis
  • Treatment
    • Ribavirin
    • JNJ 53718678
    • Enanta EDP-938
    • ASCENIV

By End User

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
  • REPORT UPDATE
    IN PROCESS
  • 2019-2032
    (In Process)
  • 2023
    (In Process)
GET A FREE SAMPLE

    man icon
    Mail icon
Consulting Services
    How will you benefit from our consulting services ?